Immunoserological aspects of idiopathic inflammatory muscle disease
- PMID: 11020964
Immunoserological aspects of idiopathic inflammatory muscle disease
Abstract
In the present study, the autoantibody profile of 31 Slovenian patients with idiopathic inflammatory muscle disease was estimated: 11 with polymyositis, 11 with dermatomyositis--both groups diagnosed according to the criteria of Bohan and Peter--and 9 with myositis-overlap syndromes. Autoantibodies against most relevant muscle specific (Jo-1, Mi-2) and non-specific antigens (PM-Scl, U1RNP, native Ro, Ro60, Ro52, and La) were detected with one or more detection techniques: counter-immunoelectrophoresis, enzyme-linked immunoassay, immunoblot and immunoprecipitation, each using different antigen preparations (native, recombinant). With counter-immunoelectrophoresis using a native antigen substrate (rabbit thymus extract), we were able to detect anti-PM-Scl antibodies more readily than with other techniques, probably due to conformational epitopes of native PM-Scl. Patients with this serological profile constituted a distinct group, sharing features of polymyositis and systemic sclerosis. Compared to previously reported data, the greater frequency of anti-Jo-1 found in all groups of patients (64-87% for PM, 18-20% for dermatomyositis and 33-44% for overlap syndromes) was probably due to the various methods used and the different clinical characteristics of patients. The greater prevalence of anti-Mi-2 antibodies in dermatomyositis patients (67%) and in particular in polymyositis patients (33%) and myositis-overlap syndromes (33%) seemed to be mainly due to methodological differences. A strikingly high prevalence of anti-Ro52 positive patients with polymyositis (55%), dermatomyositis (22%), and myositis-overlap syndromes (33%) was demonstrated, but was detected by only one technique. Moreover, concurrence with anti-Jo-1 antibodies was noted (69%).
Similar articles
-
Clinical implications of autoantibody screening in patients with autoimmune myositis.Autoimmunity. 2006 May;39(3):217-21. doi: 10.1080/08916930600622645. Autoimmunity. 2006. PMID: 16769655
-
[Spectrum of antinuclear and anti-cytoplasmic antibodies in dermatomyositis and polymyositis overlap syndromes].Hautarzt. 1989 Oct;40(10):623-9. Hautarzt. 1989. PMID: 2482267 German.
-
Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies.Autoimmun Rev. 2009 Sep;9(1):58-61. doi: 10.1016/j.autrev.2009.03.005. Epub 2009 Mar 11. Autoimmun Rev. 2009. PMID: 19285154
-
Immune manifestations of inflammatory muscle disease.Rheum Dis Clin North Am. 1994 Nov;20(4):857-80. Rheum Dis Clin North Am. 1994. PMID: 7855326 Review.
-
Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights.Autoimmun Rev. 2007 Aug;6(7):432-7. doi: 10.1016/j.autrev.2007.01.013. Epub 2007 Feb 20. Autoimmun Rev. 2007. PMID: 17643929 Review.
Cited by
-
Clinical and pathological roles of Ro/SSA autoantibody system.Clin Dev Immunol. 2012;2012:606195. doi: 10.1155/2012/606195. Epub 2012 Dec 6. Clin Dev Immunol. 2012. PMID: 23304190 Free PMC article. Review.
-
A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity.Rheumatol Int. 2017 Aug;37(8):1323-1333. doi: 10.1007/s00296-017-3718-1. Epub 2017 Apr 17. Rheumatol Int. 2017. PMID: 28417151 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous